Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average - Time to Sell?

Key Points

• Technical signal: Galapagos shares crossed below their 200‑day moving average (200‑day = $32.63), trading as low as $28.27 and last at $28.93 on Tuesday.
• Analyst view: The consensus rating is "Hold" (one Strong Buy, five Hold, one Sell) with a consensus target price of $36.50 after several recent mixed upgrades and reratings.
• Company fundamentals: Market cap is about $1.91 billion with a negative P/E (-18.43); the company reported quarterly revenue of $1.06 billion and EPS of $13.92, while analysts forecast -1.6 EPS for the current year and institutions own ~32.5% of the stock.

Galapagos NV (NASDAQ:GLPG - Get Free Report)'s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $32.63 and traded as low as $28.27. Galapagos shares last traded at $28.93, with a volume of 249,516 shares changing hands.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Raymond James Financial reissued a "market perform" rating on shares of Galapagos in a report on Tuesday, February 24th. Weiss Ratings raised Galapagos from a "sell (d)" rating to a "hold (c)" rating in a report on Thursday, February 26th. Wall Street Zen upgraded Galapagos from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. UBS Group restated a "market perform" rating on shares of Galapagos in a research report on Tuesday, February 24th. Finally, Royal Bank Of Canada boosted their price target on Galapagos from $32.00 to $33.00 and gave the company a "sector perform" rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $36.50.

Galapagos Stock Performance

The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -18.43 and a beta of 0.32. The company has a 50-day moving average of $32.61 and a 200-day moving average of $32.63.

Galapagos (NASDAQ:GLPG - Get Free Report) last issued its quarterly earnings results on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The company had revenue of $1.06 billion during the quarter. As a group, equities research analysts forecast that Galapagos NV will post -1.6 EPS for the current year.

Institutional Trading of Galapagos

Several hedge funds have recently modified their holdings of the business. EcoR1 Capital LLC boosted its stake in shares of Galapagos by 569.0% in the second quarter. EcoR1 Capital LLC now owns 1,036,945 shares of the biotechnology company's stock valued at $29,024,000 after buying an additional 881,939 shares in the last quarter. Matauro LLC purchased a new stake in shares of Galapagos in the third quarter valued at approximately $1,647,000. Norges Bank purchased a new stake in shares of Galapagos in the second quarter valued at approximately $3,359,000. Van ECK Associates Corp boosted its stake in shares of Galapagos by 61.6% in the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company's stock valued at $64,000 after buying an additional 750 shares in the last quarter. Finally, State of Wyoming purchased a new stake in shares of Galapagos in the second quarter valued at approximately $28,000. 32.46% of the stock is owned by institutional investors and hedge funds.

About Galapagos

Galapagos NV NASDAQ: GLPG is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company's discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company's pipeline encompasses multiple programs across various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.